Dr. Schuster shares results from the global JULIET trial of the CAR T-cell therapy tisagenlecleucel in patients with relapsed/refractory diffuse large B-cell lymphoma – a patient population with the “greatest unmet need.”
Recent Articles
Voxelotor Granted Priority Review for Children With Sickle Cell Disease
The U.S. Food and Drug Administration (FDA) has accepted Global Blood Therapeutics’ (GBT’s) supplemental New Drug Application (sNDA) seeking accelerated approval for voxelotor for...
Could Changing Indoor Air Quality Standards Eliminate Respiratory Illnesses?
Sewage systems in London vanquished cholera in the 19th century. Pesticides, wide-scale landscape management, and window screens that kept out mosquitos eliminated yellow fever...
Cognitive Decline Observed Six Months After Chemotherapy in Patients With Lymphoma
Patients with lymphoma tend to report and show signs of worsening cognitive function at six months after chemotherapy compared with healthy controls, according to...
Asciminib Superior to Bosutinib in Chronic-Phase CML
Asciminib was more effective than bosutinib at improving the rate of a major molecular response in patients with chronic myeloid leukemia in chronic phase...
Editor’s Corner: Check Your Bia-Cis at the Door
I know I’m a proud parent, but my teenaged sons’ respect for and acceptance of their friends’ preferred pronouns, dress, and names, as well...
Current Issue
September 2021 Volume 7 Issue 11
This issue discusses fertility preservation for young patients with cancer, reviews treatment options for primary immune thrombocytopenia, and more.